Computationally restoring the potency of a clinical antibody against SARS-CoV-2 Omicron subvariants Article Swipe
Thomas Desautels
,
Kathryn T. Arrildt
,
Adam Zemła
,
Edmond Y. Lau
,
Fangqiang Zhu
,
Dante P. Ricci
,
Stephanie E. J. Cronin
,
Seth J. Zost
,
Elad Binshtein
,
Suzanne M. Scheaffer
,
Bernadeta Dadonaite
,
Brenden K. Petersen
,
Taylor B. Engdahl
,
Elaine Chen
,
Laura S. Handal
,
Lynn Hall
,
John W. Goforth
,
Denis Vashchenko
,
Sam Nguyen
,
Dina R. Weilhammer
,
Jacky Lo
,
Bonnee Rubinfeld
,
Edwin A. Saada
,
Tracy Weisenberger
,
Tek-Hyung Lee
,
Bradley Whitener
,
James Brett Case
,
Alexander Ladd
,
Mary S. Silva
,
Rebecca M. Haluska
,
Emilia A. Grzesiak
,
Christopher G. Earnhart
,
Svetlana A. Hopkins
,
Thomas W. Bates
,
Larissa B. Thackray
,
Brent W. Segelke
,
Antonietta Lillo
,
Shivshankar Sundaram
,
Jesse D. Bloom
,
Michael S. Diamond
,
James E. Crowe
,
Robert H. Carnahan
,
Daniel Faissol
·
YOU?
·
· 2022
· Open Access
·
· DOI: https://doi.org/10.1101/2022.10.21.513237
YOU?
·
· 2022
· Open Access
·
· DOI: https://doi.org/10.1101/2022.10.21.513237
The COVID-19 pandemic underscored the promise of monoclonal antibody-based prophylactic and therapeutic drugs 1–3 , but also revealed how quickly viral escape can curtail effective options 4, 5 . With the emergence of the SARS-CoV-2 Omicron variant in late 2021, many clinically used antibody drug products lost potency, including Evusheld TM and its constituent, cilgavimab 4, 6 . Cilgavimab, like its progenitor COV2-2130, is a class 3 antibody that is compatible with other antibodies in combination 4 and is challenging to replace with existing approaches. Rapidly modifying such high-value antibodies with a known clinical profile to restore efficacy against emerging variants is a compelling mitigation strategy. We sought to redesign COV2-2130 to rescue in vivo efficacy against Omicron BA.1 and BA.1.1 strains while maintaining efficacy against the contemporaneously dominant Delta variant. Here we show that our computationally redesigned antibody, 2130-1-0114-112, achieves this objective, simultaneously increases neutralization potency against Delta and many variants of concern that subsequently emerged, and provides protection in vivo against the strains tested, WA1/2020, BA.1.1, and BA.5. Deep mutational scanning of tens of thousands pseudovirus variants reveals 2130-1-0114-112 improves broad potency without incurring additional escape liabilities. Our results suggest that computational approaches can optimize an antibody to target multiple escape variants, while simultaneously enriching potency. Because our approach is computationally driven, not requiring experimental iterations or pre-existing binding data, it could enable rapid response strategies to address escape variants or pre-emptively mitigate escape vulnerabilities.
Related Topics
Concepts
Potency
Antibody
In vivo
Neutralization
Monoclonal antibody
Coronavirus disease 2019 (COVID-19)
Computational biology
Clinical efficacy
Pandemic
Virology
Computer science
Biology
In vitro
Immunology
Medicine
Genetics
Disease
Internal medicine
Infectious disease (medical specialty)
Metadata
- Type
- preprint
- Language
- en
- Landing Page
- https://doi.org/10.1101/2022.10.21.513237
- https://www.biorxiv.org/content/biorxiv/early/2022/10/24/2022.10.21.513237.full.pdf
- OA Status
- green
- Cited By
- 5
- References
- 71
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4307280721
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4307280721Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1101/2022.10.21.513237Digital Object Identifier
- Title
-
Computationally restoring the potency of a clinical antibody against SARS-CoV-2 Omicron subvariantsWork title
- Type
-
preprintOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2022Year of publication
- Publication date
-
2022-10-24Full publication date if available
- Authors
-
Thomas Desautels, Kathryn T. Arrildt, Adam Zemła, Edmond Y. Lau, Fangqiang Zhu, Dante P. Ricci, Stephanie E. J. Cronin, Seth J. Zost, Elad Binshtein, Suzanne M. Scheaffer, Bernadeta Dadonaite, Brenden K. Petersen, Taylor B. Engdahl, Elaine Chen, Laura S. Handal, Lynn Hall, John W. Goforth, Denis Vashchenko, Sam Nguyen, Dina R. Weilhammer, Jacky Lo, Bonnee Rubinfeld, Edwin A. Saada, Tracy Weisenberger, Tek-Hyung Lee, Bradley Whitener, James Brett Case, Alexander Ladd, Mary S. Silva, Rebecca M. Haluska, Emilia A. Grzesiak, Christopher G. Earnhart, Svetlana A. Hopkins, Thomas W. Bates, Larissa B. Thackray, Brent W. Segelke, Antonietta Lillo, Shivshankar Sundaram, Jesse D. Bloom, Michael S. Diamond, James E. Crowe, Robert H. Carnahan, Daniel FaissolList of authors in order
- Landing page
-
https://doi.org/10.1101/2022.10.21.513237Publisher landing page
- PDF URL
-
https://www.biorxiv.org/content/biorxiv/early/2022/10/24/2022.10.21.513237.full.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
greenOpen access status per OpenAlex
- OA URL
-
https://www.biorxiv.org/content/biorxiv/early/2022/10/24/2022.10.21.513237.full.pdfDirect OA link when available
- Concepts
-
Potency, Antibody, In vivo, Neutralization, Monoclonal antibody, Coronavirus disease 2019 (COVID-19), Computational biology, Clinical efficacy, Pandemic, Virology, Computer science, Biology, In vitro, Immunology, Medicine, Genetics, Disease, Internal medicine, Infectious disease (medical specialty)Top concepts (fields/topics) attached by OpenAlex
- Cited by
-
5Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 2, 2024: 1, 2023: 2Per-year citation counts (last 5 years)
- References (count)
-
71Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4307280721 |
|---|---|
| doi | https://doi.org/10.1101/2022.10.21.513237 |
| ids.doi | https://doi.org/10.1101/2022.10.21.513237 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/36324800 |
| ids.openalex | https://openalex.org/W4307280721 |
| fwci | 0.62590898 |
| type | preprint |
| title | Computationally restoring the potency of a clinical antibody against SARS-CoV-2 Omicron subvariants |
| biblio.issue | |
| biblio.volume | |
| biblio.last_page | |
| biblio.first_page | |
| topics[0].id | https://openalex.org/T10118 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9995999932289124 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2725 |
| topics[0].subfield.display_name | Infectious Diseases |
| topics[0].display_name | SARS-CoV-2 and COVID-19 Research |
| topics[1].id | https://openalex.org/T11491 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9925000071525574 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2730 |
| topics[1].subfield.display_name | Oncology |
| topics[1].display_name | CAR-T cell therapy research |
| topics[2].id | https://openalex.org/T11016 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9923999905586243 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2741 |
| topics[2].subfield.display_name | Radiology, Nuclear Medicine and Imaging |
| topics[2].display_name | Monoclonal and Polyclonal Antibodies Research |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C57992300 |
| concepts[0].level | 3 |
| concepts[0].score | 0.8990565538406372 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q2066956 |
| concepts[0].display_name | Potency |
| concepts[1].id | https://openalex.org/C159654299 |
| concepts[1].level | 2 |
| concepts[1].score | 0.6875830888748169 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q79460 |
| concepts[1].display_name | Antibody |
| concepts[2].id | https://openalex.org/C207001950 |
| concepts[2].level | 2 |
| concepts[2].score | 0.580640971660614 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q141124 |
| concepts[2].display_name | In vivo |
| concepts[3].id | https://openalex.org/C14086860 |
| concepts[3].level | 3 |
| concepts[3].score | 0.5781142115592957 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q337120 |
| concepts[3].display_name | Neutralization |
| concepts[4].id | https://openalex.org/C542903549 |
| concepts[4].level | 3 |
| concepts[4].score | 0.5440965294837952 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q422248 |
| concepts[4].display_name | Monoclonal antibody |
| concepts[5].id | https://openalex.org/C3008058167 |
| concepts[5].level | 4 |
| concepts[5].score | 0.4912063479423523 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q84263196 |
| concepts[5].display_name | Coronavirus disease 2019 (COVID-19) |
| concepts[6].id | https://openalex.org/C70721500 |
| concepts[6].level | 1 |
| concepts[6].score | 0.47003549337387085 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q177005 |
| concepts[6].display_name | Computational biology |
| concepts[7].id | https://openalex.org/C2992053201 |
| concepts[7].level | 2 |
| concepts[7].score | 0.4156697690486908 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q2585693 |
| concepts[7].display_name | Clinical efficacy |
| concepts[8].id | https://openalex.org/C89623803 |
| concepts[8].level | 5 |
| concepts[8].score | 0.4140647351741791 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q12184 |
| concepts[8].display_name | Pandemic |
| concepts[9].id | https://openalex.org/C159047783 |
| concepts[9].level | 1 |
| concepts[9].score | 0.39771682024002075 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q7215 |
| concepts[9].display_name | Virology |
| concepts[10].id | https://openalex.org/C41008148 |
| concepts[10].level | 0 |
| concepts[10].score | 0.387295126914978 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q21198 |
| concepts[10].display_name | Computer science |
| concepts[11].id | https://openalex.org/C86803240 |
| concepts[11].level | 0 |
| concepts[11].score | 0.3672988712787628 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[11].display_name | Biology |
| concepts[12].id | https://openalex.org/C202751555 |
| concepts[12].level | 2 |
| concepts[12].score | 0.336210161447525 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q221681 |
| concepts[12].display_name | In vitro |
| concepts[13].id | https://openalex.org/C203014093 |
| concepts[13].level | 1 |
| concepts[13].score | 0.31082290410995483 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q101929 |
| concepts[13].display_name | Immunology |
| concepts[14].id | https://openalex.org/C71924100 |
| concepts[14].level | 0 |
| concepts[14].score | 0.286618709564209 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[14].display_name | Medicine |
| concepts[15].id | https://openalex.org/C54355233 |
| concepts[15].level | 1 |
| concepts[15].score | 0.17313361167907715 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q7162 |
| concepts[15].display_name | Genetics |
| concepts[16].id | https://openalex.org/C2779134260 |
| concepts[16].level | 2 |
| concepts[16].score | 0.11297929286956787 |
| concepts[16].wikidata | https://www.wikidata.org/wiki/Q12136 |
| concepts[16].display_name | Disease |
| concepts[17].id | https://openalex.org/C126322002 |
| concepts[17].level | 1 |
| concepts[17].score | 0.09444671869277954 |
| concepts[17].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[17].display_name | Internal medicine |
| concepts[18].id | https://openalex.org/C524204448 |
| concepts[18].level | 3 |
| concepts[18].score | 0.0 |
| concepts[18].wikidata | https://www.wikidata.org/wiki/Q788926 |
| concepts[18].display_name | Infectious disease (medical specialty) |
| keywords[0].id | https://openalex.org/keywords/potency |
| keywords[0].score | 0.8990565538406372 |
| keywords[0].display_name | Potency |
| keywords[1].id | https://openalex.org/keywords/antibody |
| keywords[1].score | 0.6875830888748169 |
| keywords[1].display_name | Antibody |
| keywords[2].id | https://openalex.org/keywords/in-vivo |
| keywords[2].score | 0.580640971660614 |
| keywords[2].display_name | In vivo |
| keywords[3].id | https://openalex.org/keywords/neutralization |
| keywords[3].score | 0.5781142115592957 |
| keywords[3].display_name | Neutralization |
| keywords[4].id | https://openalex.org/keywords/monoclonal-antibody |
| keywords[4].score | 0.5440965294837952 |
| keywords[4].display_name | Monoclonal antibody |
| keywords[5].id | https://openalex.org/keywords/coronavirus-disease-2019 |
| keywords[5].score | 0.4912063479423523 |
| keywords[5].display_name | Coronavirus disease 2019 (COVID-19) |
| keywords[6].id | https://openalex.org/keywords/computational-biology |
| keywords[6].score | 0.47003549337387085 |
| keywords[6].display_name | Computational biology |
| keywords[7].id | https://openalex.org/keywords/clinical-efficacy |
| keywords[7].score | 0.4156697690486908 |
| keywords[7].display_name | Clinical efficacy |
| keywords[8].id | https://openalex.org/keywords/pandemic |
| keywords[8].score | 0.4140647351741791 |
| keywords[8].display_name | Pandemic |
| keywords[9].id | https://openalex.org/keywords/virology |
| keywords[9].score | 0.39771682024002075 |
| keywords[9].display_name | Virology |
| keywords[10].id | https://openalex.org/keywords/computer-science |
| keywords[10].score | 0.387295126914978 |
| keywords[10].display_name | Computer science |
| keywords[11].id | https://openalex.org/keywords/biology |
| keywords[11].score | 0.3672988712787628 |
| keywords[11].display_name | Biology |
| keywords[12].id | https://openalex.org/keywords/in-vitro |
| keywords[12].score | 0.336210161447525 |
| keywords[12].display_name | In vitro |
| keywords[13].id | https://openalex.org/keywords/immunology |
| keywords[13].score | 0.31082290410995483 |
| keywords[13].display_name | Immunology |
| keywords[14].id | https://openalex.org/keywords/medicine |
| keywords[14].score | 0.286618709564209 |
| keywords[14].display_name | Medicine |
| keywords[15].id | https://openalex.org/keywords/genetics |
| keywords[15].score | 0.17313361167907715 |
| keywords[15].display_name | Genetics |
| keywords[16].id | https://openalex.org/keywords/disease |
| keywords[16].score | 0.11297929286956787 |
| keywords[16].display_name | Disease |
| keywords[17].id | https://openalex.org/keywords/internal-medicine |
| keywords[17].score | 0.09444671869277954 |
| keywords[17].display_name | Internal medicine |
| language | en |
| locations[0].id | doi:10.1101/2022.10.21.513237 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S4306402567 |
| locations[0].source.issn | |
| locations[0].source.type | repository |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | |
| locations[0].source.is_core | False |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | bioRxiv (Cold Spring Harbor Laboratory) |
| locations[0].source.host_organization | https://openalex.org/I2750212522 |
| locations[0].source.host_organization_name | Cold Spring Harbor Laboratory |
| locations[0].source.host_organization_lineage | https://openalex.org/I2750212522 |
| locations[0].license | cc-by-nd |
| locations[0].pdf_url | https://www.biorxiv.org/content/biorxiv/early/2022/10/24/2022.10.21.513237.full.pdf |
| locations[0].version | acceptedVersion |
| locations[0].raw_type | posted-content |
| locations[0].license_id | https://openalex.org/licenses/cc-by-nd |
| locations[0].is_accepted | True |
| locations[0].is_published | False |
| locations[0].raw_source_name | |
| locations[0].landing_page_url | https://doi.org/10.1101/2022.10.21.513237 |
| locations[1].id | pmid:36324800 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | bioRxiv : the preprint server for biology |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/36324800 |
| locations[2].id | pmh:oai:pubmedcentral.nih.gov:9628197 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S2764455111 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | PubMed Central |
| locations[2].source.host_organization | https://openalex.org/I1299303238 |
| locations[2].source.host_organization_name | National Institutes of Health |
| locations[2].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[2].license | |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Text |
| locations[2].license_id | |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | bioRxiv |
| locations[2].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/9628197 |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5087606710 |
| authorships[0].author.orcid | https://orcid.org/0000-0001-6853-981X |
| authorships[0].author.display_name | Thomas Desautels |
| authorships[0].countries | US |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I1282311441 |
| authorships[0].affiliations[0].raw_affiliation_string | Computational Engineering Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA |
| authorships[0].institutions[0].id | https://openalex.org/I1282311441 |
| authorships[0].institutions[0].ror | https://ror.org/041nk4h53 |
| authorships[0].institutions[0].type | facility |
| authorships[0].institutions[0].lineage | https://openalex.org/I1282311441, https://openalex.org/I1330989302, https://openalex.org/I198811213, https://openalex.org/I4210138311 |
| authorships[0].institutions[0].country_code | US |
| authorships[0].institutions[0].display_name | Lawrence Livermore National Laboratory |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Thomas A. Desautels |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Computational Engineering Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA |
| authorships[1].author.id | https://openalex.org/A5076617901 |
| authorships[1].author.orcid | https://orcid.org/0000-0001-6329-6214 |
| authorships[1].author.display_name | Kathryn T. Arrildt |
| authorships[1].countries | US |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I1282311441 |
| authorships[1].affiliations[0].raw_affiliation_string | Biosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA |
| authorships[1].institutions[0].id | https://openalex.org/I1282311441 |
| authorships[1].institutions[0].ror | https://ror.org/041nk4h53 |
| authorships[1].institutions[0].type | facility |
| authorships[1].institutions[0].lineage | https://openalex.org/I1282311441, https://openalex.org/I1330989302, https://openalex.org/I198811213, https://openalex.org/I4210138311 |
| authorships[1].institutions[0].country_code | US |
| authorships[1].institutions[0].display_name | Lawrence Livermore National Laboratory |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Kathryn T. Arrildt |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Biosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA |
| authorships[2].author.id | https://openalex.org/A5083445132 |
| authorships[2].author.orcid | https://orcid.org/0000-0003-0504-8647 |
| authorships[2].author.display_name | Adam Zemła |
| authorships[2].countries | US |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I1282311441, https://openalex.org/I4210138311 |
| authorships[2].affiliations[0].raw_affiliation_string | Global Security Computing Applications Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA |
| authorships[2].institutions[0].id | https://openalex.org/I1282311441 |
| authorships[2].institutions[0].ror | https://ror.org/041nk4h53 |
| authorships[2].institutions[0].type | facility |
| authorships[2].institutions[0].lineage | https://openalex.org/I1282311441, https://openalex.org/I1330989302, https://openalex.org/I198811213, https://openalex.org/I4210138311 |
| authorships[2].institutions[0].country_code | US |
| authorships[2].institutions[0].display_name | Lawrence Livermore National Laboratory |
| authorships[2].institutions[1].id | https://openalex.org/I4210138311 |
| authorships[2].institutions[1].ror | https://ror.org/03z21mf61 |
| authorships[2].institutions[1].type | government |
| authorships[2].institutions[1].lineage | https://openalex.org/I4210138311 |
| authorships[2].institutions[1].country_code | US |
| authorships[2].institutions[1].display_name | Lawrence Livermore National Security |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Adam T. Zemla |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Global Security Computing Applications Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA |
| authorships[3].author.id | https://openalex.org/A5016987266 |
| authorships[3].author.orcid | https://orcid.org/0000-0003-0619-7249 |
| authorships[3].author.display_name | Edmond Y. Lau |
| authorships[3].countries | US |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I1282311441 |
| authorships[3].affiliations[0].raw_affiliation_string | Biosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA |
| authorships[3].institutions[0].id | https://openalex.org/I1282311441 |
| authorships[3].institutions[0].ror | https://ror.org/041nk4h53 |
| authorships[3].institutions[0].type | facility |
| authorships[3].institutions[0].lineage | https://openalex.org/I1282311441, https://openalex.org/I1330989302, https://openalex.org/I198811213, https://openalex.org/I4210138311 |
| authorships[3].institutions[0].country_code | US |
| authorships[3].institutions[0].display_name | Lawrence Livermore National Laboratory |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Edmond Y. Lau |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Biosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA |
| authorships[4].author.id | https://openalex.org/A5079002066 |
| authorships[4].author.orcid | https://orcid.org/0000-0001-6202-2262 |
| authorships[4].author.display_name | Fangqiang Zhu |
| authorships[4].countries | US |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I1282311441 |
| authorships[4].affiliations[0].raw_affiliation_string | Biosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA |
| authorships[4].institutions[0].id | https://openalex.org/I1282311441 |
| authorships[4].institutions[0].ror | https://ror.org/041nk4h53 |
| authorships[4].institutions[0].type | facility |
| authorships[4].institutions[0].lineage | https://openalex.org/I1282311441, https://openalex.org/I1330989302, https://openalex.org/I198811213, https://openalex.org/I4210138311 |
| authorships[4].institutions[0].country_code | US |
| authorships[4].institutions[0].display_name | Lawrence Livermore National Laboratory |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Fangqiang Zhu |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Biosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA |
| authorships[5].author.id | https://openalex.org/A5007700514 |
| authorships[5].author.orcid | https://orcid.org/0000-0003-4448-6076 |
| authorships[5].author.display_name | Dante P. Ricci |
| authorships[5].countries | US |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I1282311441 |
| authorships[5].affiliations[0].raw_affiliation_string | Biosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA |
| authorships[5].institutions[0].id | https://openalex.org/I1282311441 |
| authorships[5].institutions[0].ror | https://ror.org/041nk4h53 |
| authorships[5].institutions[0].type | facility |
| authorships[5].institutions[0].lineage | https://openalex.org/I1282311441, https://openalex.org/I1330989302, https://openalex.org/I198811213, https://openalex.org/I4210138311 |
| authorships[5].institutions[0].country_code | US |
| authorships[5].institutions[0].display_name | Lawrence Livermore National Laboratory |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Dante Ricci |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Biosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA |
| authorships[6].author.id | https://openalex.org/A5060279411 |
| authorships[6].author.orcid | https://orcid.org/0000-0002-8462-4050 |
| authorships[6].author.display_name | Stephanie E. J. Cronin |
| authorships[6].affiliations[0].raw_affiliation_string | Vanderbilt Vaccine Center, Nashville, TN 3232, USA |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Stephanie Cronin |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Vanderbilt Vaccine Center, Nashville, TN 3232, USA |
| authorships[7].author.id | https://openalex.org/A5076540073 |
| authorships[7].author.orcid | https://orcid.org/0000-0001-6712-5076 |
| authorships[7].author.display_name | Seth J. Zost |
| authorships[7].countries | US |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I1282311441, https://openalex.org/I4210138311 |
| authorships[7].affiliations[0].raw_affiliation_string | Computational Engineering Division 1 , Biosciences and Biotechnology Division 2 , Global Security Computing Applications Division 3 , Applications Simulations and Quality Division 4 , Global Security Directorate 5 , Center for Bioengineering 6 , Lawrence Livermore National Laboratory, Livermore, CA 94550, USA. |
| authorships[7].affiliations[1].raw_affiliation_string | Vanderbilt Vaccine Center, Nashville, TN 37232, USA |
| authorships[7].institutions[0].id | https://openalex.org/I1282311441 |
| authorships[7].institutions[0].ror | https://ror.org/041nk4h53 |
| authorships[7].institutions[0].type | facility |
| authorships[7].institutions[0].lineage | https://openalex.org/I1282311441, https://openalex.org/I1330989302, https://openalex.org/I198811213, https://openalex.org/I4210138311 |
| authorships[7].institutions[0].country_code | US |
| authorships[7].institutions[0].display_name | Lawrence Livermore National Laboratory |
| authorships[7].institutions[1].id | https://openalex.org/I4210138311 |
| authorships[7].institutions[1].ror | https://ror.org/03z21mf61 |
| authorships[7].institutions[1].type | government |
| authorships[7].institutions[1].lineage | https://openalex.org/I4210138311 |
| authorships[7].institutions[1].country_code | US |
| authorships[7].institutions[1].display_name | Lawrence Livermore National Security |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Seth J. Zost |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Computational Engineering Division 1 , Biosciences and Biotechnology Division 2 , Global Security Computing Applications Division 3 , Applications Simulations and Quality Division 4 , Global Security Directorate 5 , Center for Bioengineering 6 , Lawrence Livermore National Laboratory, Livermore, CA 94550, USA., Vanderbilt Vaccine Center, Nashville, TN 37232, USA |
| authorships[8].author.id | https://openalex.org/A5053212751 |
| authorships[8].author.orcid | https://orcid.org/0000-0003-2745-104X |
| authorships[8].author.display_name | Elad Binshtein |
| authorships[8].affiliations[0].raw_affiliation_string | Vanderbilt Vaccine Center, Nashville, TN 3232, USA |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Elad Binshtein |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Vanderbilt Vaccine Center, Nashville, TN 3232, USA |
| authorships[9].author.id | https://openalex.org/A5081075487 |
| authorships[9].author.orcid | https://orcid.org/0009-0001-0459-0816 |
| authorships[9].author.display_name | Suzanne M. Scheaffer |
| authorships[9].countries | US |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I204465549 |
| authorships[9].affiliations[0].raw_affiliation_string | Departments of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA |
| authorships[9].institutions[0].id | https://openalex.org/I204465549 |
| authorships[9].institutions[0].ror | https://ror.org/01yc7t268 |
| authorships[9].institutions[0].type | education |
| authorships[9].institutions[0].lineage | https://openalex.org/I204465549 |
| authorships[9].institutions[0].country_code | US |
| authorships[9].institutions[0].display_name | Washington University in St. Louis |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Suzanne M. Scheaffer |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Departments of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA |
| authorships[10].author.id | https://openalex.org/A5074204515 |
| authorships[10].author.orcid | https://orcid.org/0000-0003-0908-6982 |
| authorships[10].author.display_name | Bernadeta Dadonaite |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Bernadeta Dadonaite |
| authorships[10].is_corresponding | False |
| authorships[11].author.id | https://openalex.org/A5055746866 |
| authorships[11].author.orcid | https://orcid.org/0000-0002-1841-3888 |
| authorships[11].author.display_name | Brenden K. Petersen |
| authorships[11].countries | US |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I1282311441 |
| authorships[11].affiliations[0].raw_affiliation_string | Computational Engineering Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA |
| authorships[11].institutions[0].id | https://openalex.org/I1282311441 |
| authorships[11].institutions[0].ror | https://ror.org/041nk4h53 |
| authorships[11].institutions[0].type | facility |
| authorships[11].institutions[0].lineage | https://openalex.org/I1282311441, https://openalex.org/I1330989302, https://openalex.org/I198811213, https://openalex.org/I4210138311 |
| authorships[11].institutions[0].country_code | US |
| authorships[11].institutions[0].display_name | Lawrence Livermore National Laboratory |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Brenden K. Petersen |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | Computational Engineering Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA |
| authorships[12].author.id | https://openalex.org/A5072589659 |
| authorships[12].author.orcid | https://orcid.org/0000-0002-6280-4405 |
| authorships[12].author.display_name | Taylor B. Engdahl |
| authorships[12].affiliations[0].raw_affiliation_string | Vanderbilt Vaccine Center, Nashville, TN 3232, USA |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | Taylor B. Engdahl |
| authorships[12].is_corresponding | False |
| authorships[12].raw_affiliation_strings | Vanderbilt Vaccine Center, Nashville, TN 3232, USA |
| authorships[13].author.id | https://openalex.org/A5036169660 |
| authorships[13].author.orcid | https://orcid.org/0000-0001-5446-137X |
| authorships[13].author.display_name | Elaine Chen |
| authorships[13].affiliations[0].raw_affiliation_string | Vanderbilt Vaccine Center, Nashville, TN 3232, USA |
| authorships[13].author_position | middle |
| authorships[13].raw_author_name | Elaine Chen |
| authorships[13].is_corresponding | False |
| authorships[13].raw_affiliation_strings | Vanderbilt Vaccine Center, Nashville, TN 3232, USA |
| authorships[14].author.id | https://openalex.org/A5014424081 |
| authorships[14].author.orcid | https://orcid.org/0000-0001-8658-4411 |
| authorships[14].author.display_name | Laura S. Handal |
| authorships[14].author_position | middle |
| authorships[14].raw_author_name | Laura S. Handal |
| authorships[14].is_corresponding | False |
| authorships[15].author.id | https://openalex.org/A5015385043 |
| authorships[15].author.orcid | https://orcid.org/0000-0002-2604-8104 |
| authorships[15].author.display_name | Lynn Hall |
| authorships[15].author_position | middle |
| authorships[15].raw_author_name | Lynn Hall |
| authorships[15].is_corresponding | False |
| authorships[16].author.id | https://openalex.org/A5112875634 |
| authorships[16].author.orcid | |
| authorships[16].author.display_name | John W. Goforth |
| authorships[16].countries | US |
| authorships[16].affiliations[0].institution_ids | https://openalex.org/I1282311441, https://openalex.org/I4210138311 |
| authorships[16].affiliations[0].raw_affiliation_string | Global Security Computing Applications Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA |
| authorships[16].institutions[0].id | https://openalex.org/I1282311441 |
| authorships[16].institutions[0].ror | https://ror.org/041nk4h53 |
| authorships[16].institutions[0].type | facility |
| authorships[16].institutions[0].lineage | https://openalex.org/I1282311441, https://openalex.org/I1330989302, https://openalex.org/I198811213, https://openalex.org/I4210138311 |
| authorships[16].institutions[0].country_code | US |
| authorships[16].institutions[0].display_name | Lawrence Livermore National Laboratory |
| authorships[16].institutions[1].id | https://openalex.org/I4210138311 |
| authorships[16].institutions[1].ror | https://ror.org/03z21mf61 |
| authorships[16].institutions[1].type | government |
| authorships[16].institutions[1].lineage | https://openalex.org/I4210138311 |
| authorships[16].institutions[1].country_code | US |
| authorships[16].institutions[1].display_name | Lawrence Livermore National Security |
| authorships[16].author_position | middle |
| authorships[16].raw_author_name | John W. Goforth |
| authorships[16].is_corresponding | False |
| authorships[16].raw_affiliation_strings | Global Security Computing Applications Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA |
| authorships[17].author.id | https://openalex.org/A5024455977 |
| authorships[17].author.orcid | |
| authorships[17].author.display_name | Denis Vashchenko |
| authorships[17].countries | US |
| authorships[17].affiliations[0].institution_ids | https://openalex.org/I1282311441 |
| authorships[17].affiliations[0].raw_affiliation_string | Applications Simulations and Quality Division, Lawrence Livermore National Laboratory, Livermore, CA 9550, USA |
| authorships[17].institutions[0].id | https://openalex.org/I1282311441 |
| authorships[17].institutions[0].ror | https://ror.org/041nk4h53 |
| authorships[17].institutions[0].type | facility |
| authorships[17].institutions[0].lineage | https://openalex.org/I1282311441, https://openalex.org/I1330989302, https://openalex.org/I198811213, https://openalex.org/I4210138311 |
| authorships[17].institutions[0].country_code | US |
| authorships[17].institutions[0].display_name | Lawrence Livermore National Laboratory |
| authorships[17].author_position | middle |
| authorships[17].raw_author_name | Denis Vashchenko |
| authorships[17].is_corresponding | False |
| authorships[17].raw_affiliation_strings | Applications Simulations and Quality Division, Lawrence Livermore National Laboratory, Livermore, CA 9550, USA |
| authorships[18].author.id | https://openalex.org/A5075408736 |
| authorships[18].author.orcid | |
| authorships[18].author.display_name | Sam Nguyen |
| authorships[18].countries | US |
| authorships[18].affiliations[0].institution_ids | https://openalex.org/I1282311441 |
| authorships[18].affiliations[0].raw_affiliation_string | Computational Engineering Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA |
| authorships[18].institutions[0].id | https://openalex.org/I1282311441 |
| authorships[18].institutions[0].ror | https://ror.org/041nk4h53 |
| authorships[18].institutions[0].type | facility |
| authorships[18].institutions[0].lineage | https://openalex.org/I1282311441, https://openalex.org/I1330989302, https://openalex.org/I198811213, https://openalex.org/I4210138311 |
| authorships[18].institutions[0].country_code | US |
| authorships[18].institutions[0].display_name | Lawrence Livermore National Laboratory |
| authorships[18].author_position | middle |
| authorships[18].raw_author_name | Sam Nguyen |
| authorships[18].is_corresponding | False |
| authorships[18].raw_affiliation_strings | Computational Engineering Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA |
| authorships[19].author.id | https://openalex.org/A5065294865 |
| authorships[19].author.orcid | https://orcid.org/0000-0002-7618-4702 |
| authorships[19].author.display_name | Dina R. Weilhammer |
| authorships[19].countries | US |
| authorships[19].affiliations[0].institution_ids | https://openalex.org/I1282311441 |
| authorships[19].affiliations[0].raw_affiliation_string | Biosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA |
| authorships[19].institutions[0].id | https://openalex.org/I1282311441 |
| authorships[19].institutions[0].ror | https://ror.org/041nk4h53 |
| authorships[19].institutions[0].type | facility |
| authorships[19].institutions[0].lineage | https://openalex.org/I1282311441, https://openalex.org/I1330989302, https://openalex.org/I198811213, https://openalex.org/I4210138311 |
| authorships[19].institutions[0].country_code | US |
| authorships[19].institutions[0].display_name | Lawrence Livermore National Laboratory |
| authorships[19].author_position | middle |
| authorships[19].raw_author_name | Dina R. Weilhammer |
| authorships[19].is_corresponding | False |
| authorships[19].raw_affiliation_strings | Biosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA |
| authorships[20].author.id | https://openalex.org/A5020278423 |
| authorships[20].author.orcid | https://orcid.org/0000-0002-4604-1751 |
| authorships[20].author.display_name | Jacky Lo |
| authorships[20].countries | US |
| authorships[20].affiliations[0].institution_ids | https://openalex.org/I1282311441 |
| authorships[20].affiliations[0].raw_affiliation_string | Biosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA |
| authorships[20].institutions[0].id | https://openalex.org/I1282311441 |
| authorships[20].institutions[0].ror | https://ror.org/041nk4h53 |
| authorships[20].institutions[0].type | facility |
| authorships[20].institutions[0].lineage | https://openalex.org/I1282311441, https://openalex.org/I1330989302, https://openalex.org/I198811213, https://openalex.org/I4210138311 |
| authorships[20].institutions[0].country_code | US |
| authorships[20].institutions[0].display_name | Lawrence Livermore National Laboratory |
| authorships[20].author_position | middle |
| authorships[20].raw_author_name | Jacky Kai-Yin Lo |
| authorships[20].is_corresponding | False |
| authorships[20].raw_affiliation_strings | Biosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA |
| authorships[21].author.id | https://openalex.org/A5006933075 |
| authorships[21].author.orcid | https://orcid.org/0000-0001-9861-6775 |
| authorships[21].author.display_name | Bonnee Rubinfeld |
| authorships[21].countries | US |
| authorships[21].affiliations[0].institution_ids | https://openalex.org/I1282311441 |
| authorships[21].affiliations[0].raw_affiliation_string | Biosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA |
| authorships[21].institutions[0].id | https://openalex.org/I1282311441 |
| authorships[21].institutions[0].ror | https://ror.org/041nk4h53 |
| authorships[21].institutions[0].type | facility |
| authorships[21].institutions[0].lineage | https://openalex.org/I1282311441, https://openalex.org/I1330989302, https://openalex.org/I198811213, https://openalex.org/I4210138311 |
| authorships[21].institutions[0].country_code | US |
| authorships[21].institutions[0].display_name | Lawrence Livermore National Laboratory |
| authorships[21].author_position | middle |
| authorships[21].raw_author_name | Bonnee Rubinfeld |
| authorships[21].is_corresponding | False |
| authorships[21].raw_affiliation_strings | Biosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA |
| authorships[22].author.id | https://openalex.org/A5013753659 |
| authorships[22].author.orcid | https://orcid.org/0000-0003-3699-1849 |
| authorships[22].author.display_name | Edwin A. Saada |
| authorships[22].countries | US |
| authorships[22].affiliations[0].institution_ids | https://openalex.org/I1282311441 |
| authorships[22].affiliations[0].raw_affiliation_string | Biosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA |
| authorships[22].institutions[0].id | https://openalex.org/I1282311441 |
| authorships[22].institutions[0].ror | https://ror.org/041nk4h53 |
| authorships[22].institutions[0].type | facility |
| authorships[22].institutions[0].lineage | https://openalex.org/I1282311441, https://openalex.org/I1330989302, https://openalex.org/I198811213, https://openalex.org/I4210138311 |
| authorships[22].institutions[0].country_code | US |
| authorships[22].institutions[0].display_name | Lawrence Livermore National Laboratory |
| authorships[22].author_position | middle |
| authorships[22].raw_author_name | Edwin A. Saada |
| authorships[22].is_corresponding | False |
| authorships[22].raw_affiliation_strings | Biosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA |
| authorships[23].author.id | https://openalex.org/A5075724163 |
| authorships[23].author.orcid | https://orcid.org/0000-0002-5849-2103 |
| authorships[23].author.display_name | Tracy Weisenberger |
| authorships[23].countries | US |
| authorships[23].affiliations[0].institution_ids | https://openalex.org/I1282311441 |
| authorships[23].affiliations[0].raw_affiliation_string | Biosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA |
| authorships[23].institutions[0].id | https://openalex.org/I1282311441 |
| authorships[23].institutions[0].ror | https://ror.org/041nk4h53 |
| authorships[23].institutions[0].type | facility |
| authorships[23].institutions[0].lineage | https://openalex.org/I1282311441, https://openalex.org/I1330989302, https://openalex.org/I198811213, https://openalex.org/I4210138311 |
| authorships[23].institutions[0].country_code | US |
| authorships[23].institutions[0].display_name | Lawrence Livermore National Laboratory |
| authorships[23].author_position | middle |
| authorships[23].raw_author_name | Tracy Weisenberger |
| authorships[23].is_corresponding | False |
| authorships[23].raw_affiliation_strings | Biosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA |
| authorships[24].author.id | https://openalex.org/A5069429488 |
| authorships[24].author.orcid | https://orcid.org/0000-0002-8299-0401 |
| authorships[24].author.display_name | Tek-Hyung Lee |
| authorships[24].countries | US |
| authorships[24].affiliations[0].institution_ids | https://openalex.org/I1282311441 |
| authorships[24].affiliations[0].raw_affiliation_string | Biosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA |
| authorships[24].institutions[0].id | https://openalex.org/I1282311441 |
| authorships[24].institutions[0].ror | https://ror.org/041nk4h53 |
| authorships[24].institutions[0].type | facility |
| authorships[24].institutions[0].lineage | https://openalex.org/I1282311441, https://openalex.org/I1330989302, https://openalex.org/I198811213, https://openalex.org/I4210138311 |
| authorships[24].institutions[0].country_code | US |
| authorships[24].institutions[0].display_name | Lawrence Livermore National Laboratory |
| authorships[24].author_position | middle |
| authorships[24].raw_author_name | Tek-Hyung Lee |
| authorships[24].is_corresponding | False |
| authorships[24].raw_affiliation_strings | Biosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA |
| authorships[25].author.id | https://openalex.org/A5058123398 |
| authorships[25].author.orcid | https://orcid.org/0000-0001-6652-0701 |
| authorships[25].author.display_name | Bradley Whitener |
| authorships[25].countries | US |
| authorships[25].affiliations[0].institution_ids | https://openalex.org/I204465549 |
| authorships[25].affiliations[0].raw_affiliation_string | Departments of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA |
| authorships[25].institutions[0].id | https://openalex.org/I204465549 |
| authorships[25].institutions[0].ror | https://ror.org/01yc7t268 |
| authorships[25].institutions[0].type | education |
| authorships[25].institutions[0].lineage | https://openalex.org/I204465549 |
| authorships[25].institutions[0].country_code | US |
| authorships[25].institutions[0].display_name | Washington University in St. Louis |
| authorships[25].author_position | middle |
| authorships[25].raw_author_name | Bradley Whitener |
| authorships[25].is_corresponding | False |
| authorships[25].raw_affiliation_strings | Departments of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA |
| authorships[26].author.id | https://openalex.org/A5036962368 |
| authorships[26].author.orcid | https://orcid.org/0000-0001-7331-5511 |
| authorships[26].author.display_name | James Brett Case |
| authorships[26].countries | US |
| authorships[26].affiliations[0].institution_ids | https://openalex.org/I204465549 |
| authorships[26].affiliations[0].raw_affiliation_string | Departments of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA |
| authorships[26].institutions[0].id | https://openalex.org/I204465549 |
| authorships[26].institutions[0].ror | https://ror.org/01yc7t268 |
| authorships[26].institutions[0].type | education |
| authorships[26].institutions[0].lineage | https://openalex.org/I204465549 |
| authorships[26].institutions[0].country_code | US |
| authorships[26].institutions[0].display_name | Washington University in St. Louis |
| authorships[26].author_position | middle |
| authorships[26].raw_author_name | James B. Case |
| authorships[26].is_corresponding | False |
| authorships[26].raw_affiliation_strings | Departments of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA |
| authorships[27].author.id | https://openalex.org/A5069478267 |
| authorships[27].author.orcid | https://orcid.org/0000-0003-0999-1608 |
| authorships[27].author.display_name | Alexander Ladd |
| authorships[27].countries | US |
| authorships[27].affiliations[0].institution_ids | https://openalex.org/I1282311441 |
| authorships[27].affiliations[0].raw_affiliation_string | Computational Engineering Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA |
| authorships[27].institutions[0].id | https://openalex.org/I1282311441 |
| authorships[27].institutions[0].ror | https://ror.org/041nk4h53 |
| authorships[27].institutions[0].type | facility |
| authorships[27].institutions[0].lineage | https://openalex.org/I1282311441, https://openalex.org/I1330989302, https://openalex.org/I198811213, https://openalex.org/I4210138311 |
| authorships[27].institutions[0].country_code | US |
| authorships[27].institutions[0].display_name | Lawrence Livermore National Laboratory |
| authorships[27].author_position | middle |
| authorships[27].raw_author_name | Alexander Ladd |
| authorships[27].is_corresponding | False |
| authorships[27].raw_affiliation_strings | Computational Engineering Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA |
| authorships[28].author.id | https://openalex.org/A5083726334 |
| authorships[28].author.orcid | |
| authorships[28].author.display_name | Mary S. Silva |
| authorships[28].countries | US |
| authorships[28].affiliations[0].institution_ids | https://openalex.org/I1282311441, https://openalex.org/I4210138311 |
| authorships[28].affiliations[0].raw_affiliation_string | Global Security Computing Applications Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA |
| authorships[28].institutions[0].id | https://openalex.org/I1282311441 |
| authorships[28].institutions[0].ror | https://ror.org/041nk4h53 |
| authorships[28].institutions[0].type | facility |
| authorships[28].institutions[0].lineage | https://openalex.org/I1282311441, https://openalex.org/I1330989302, https://openalex.org/I198811213, https://openalex.org/I4210138311 |
| authorships[28].institutions[0].country_code | US |
| authorships[28].institutions[0].display_name | Lawrence Livermore National Laboratory |
| authorships[28].institutions[1].id | https://openalex.org/I4210138311 |
| authorships[28].institutions[1].ror | https://ror.org/03z21mf61 |
| authorships[28].institutions[1].type | government |
| authorships[28].institutions[1].lineage | https://openalex.org/I4210138311 |
| authorships[28].institutions[1].country_code | US |
| authorships[28].institutions[1].display_name | Lawrence Livermore National Security |
| authorships[28].author_position | middle |
| authorships[28].raw_author_name | Mary S. Silva |
| authorships[28].is_corresponding | False |
| authorships[28].raw_affiliation_strings | Global Security Computing Applications Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA |
| authorships[29].author.id | https://openalex.org/A5041908629 |
| authorships[29].author.orcid | |
| authorships[29].author.display_name | Rebecca M. Haluska |
| authorships[29].countries | US |
| authorships[29].affiliations[0].institution_ids | https://openalex.org/I1282311441 |
| authorships[29].affiliations[0].raw_affiliation_string | Applications Simulations and Quality Division, Lawrence Livermore National Laboratory, Livermore, CA 9550, USA |
| authorships[29].institutions[0].id | https://openalex.org/I1282311441 |
| authorships[29].institutions[0].ror | https://ror.org/041nk4h53 |
| authorships[29].institutions[0].type | facility |
| authorships[29].institutions[0].lineage | https://openalex.org/I1282311441, https://openalex.org/I1330989302, https://openalex.org/I198811213, https://openalex.org/I4210138311 |
| authorships[29].institutions[0].country_code | US |
| authorships[29].institutions[0].display_name | Lawrence Livermore National Laboratory |
| authorships[29].author_position | middle |
| authorships[29].raw_author_name | Rebecca M. Haluska |
| authorships[29].is_corresponding | False |
| authorships[29].raw_affiliation_strings | Applications Simulations and Quality Division, Lawrence Livermore National Laboratory, Livermore, CA 9550, USA |
| authorships[30].author.id | https://openalex.org/A5084205202 |
| authorships[30].author.orcid | https://orcid.org/0000-0002-2453-4870 |
| authorships[30].author.display_name | Emilia A. Grzesiak |
| authorships[30].countries | US |
| authorships[30].affiliations[0].institution_ids | https://openalex.org/I1282311441, https://openalex.org/I4210138311 |
| authorships[30].affiliations[0].raw_affiliation_string | Global Security Computing Applications Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA |
| authorships[30].institutions[0].id | https://openalex.org/I1282311441 |
| authorships[30].institutions[0].ror | https://ror.org/041nk4h53 |
| authorships[30].institutions[0].type | facility |
| authorships[30].institutions[0].lineage | https://openalex.org/I1282311441, https://openalex.org/I1330989302, https://openalex.org/I198811213, https://openalex.org/I4210138311 |
| authorships[30].institutions[0].country_code | US |
| authorships[30].institutions[0].display_name | Lawrence Livermore National Laboratory |
| authorships[30].institutions[1].id | https://openalex.org/I4210138311 |
| authorships[30].institutions[1].ror | https://ror.org/03z21mf61 |
| authorships[30].institutions[1].type | government |
| authorships[30].institutions[1].lineage | https://openalex.org/I4210138311 |
| authorships[30].institutions[1].country_code | US |
| authorships[30].institutions[1].display_name | Lawrence Livermore National Security |
| authorships[30].author_position | middle |
| authorships[30].raw_author_name | Emilia A. Grzesiak |
| authorships[30].is_corresponding | False |
| authorships[30].raw_affiliation_strings | Global Security Computing Applications Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA |
| authorships[31].author.id | https://openalex.org/A5013009460 |
| authorships[31].author.orcid | |
| authorships[31].author.display_name | Christopher G. Earnhart |
| authorships[31].author_position | middle |
| authorships[31].raw_author_name | Christopher G. Earnhart |
| authorships[31].is_corresponding | False |
| authorships[32].author.id | https://openalex.org/A5003819554 |
| authorships[32].author.orcid | |
| authorships[32].author.display_name | Svetlana A. Hopkins |
| authorships[32].author_position | middle |
| authorships[32].raw_author_name | Svetlana Hopkins |
| authorships[32].is_corresponding | False |
| authorships[33].author.id | https://openalex.org/A5043692130 |
| authorships[33].author.orcid | https://orcid.org/0000-0002-0660-8266 |
| authorships[33].author.display_name | Thomas W. Bates |
| authorships[33].countries | US |
| authorships[33].affiliations[0].institution_ids | https://openalex.org/I1282311441, https://openalex.org/I4210138311 |
| authorships[33].affiliations[0].raw_affiliation_string | Global Security Directorate, Lawrence Livermore National Laboratory, Livermore, CA 940, USA |
| authorships[33].institutions[0].id | https://openalex.org/I1282311441 |
| authorships[33].institutions[0].ror | https://ror.org/041nk4h53 |
| authorships[33].institutions[0].type | facility |
| authorships[33].institutions[0].lineage | https://openalex.org/I1282311441, https://openalex.org/I1330989302, https://openalex.org/I198811213, https://openalex.org/I4210138311 |
| authorships[33].institutions[0].country_code | US |
| authorships[33].institutions[0].display_name | Lawrence Livermore National Laboratory |
| authorships[33].institutions[1].id | https://openalex.org/I4210138311 |
| authorships[33].institutions[1].ror | https://ror.org/03z21mf61 |
| authorships[33].institutions[1].type | government |
| authorships[33].institutions[1].lineage | https://openalex.org/I4210138311 |
| authorships[33].institutions[1].country_code | US |
| authorships[33].institutions[1].display_name | Lawrence Livermore National Security |
| authorships[33].author_position | middle |
| authorships[33].raw_author_name | Thomas W. Bates |
| authorships[33].is_corresponding | False |
| authorships[33].raw_affiliation_strings | Global Security Directorate, Lawrence Livermore National Laboratory, Livermore, CA 940, USA |
| authorships[34].author.id | https://openalex.org/A5036492154 |
| authorships[34].author.orcid | https://orcid.org/0000-0002-9380-6569 |
| authorships[34].author.display_name | Larissa B. Thackray |
| authorships[34].countries | US |
| authorships[34].affiliations[0].institution_ids | https://openalex.org/I204465549 |
| authorships[34].affiliations[0].raw_affiliation_string | Departments of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA |
| authorships[34].institutions[0].id | https://openalex.org/I204465549 |
| authorships[34].institutions[0].ror | https://ror.org/01yc7t268 |
| authorships[34].institutions[0].type | education |
| authorships[34].institutions[0].lineage | https://openalex.org/I204465549 |
| authorships[34].institutions[0].country_code | US |
| authorships[34].institutions[0].display_name | Washington University in St. Louis |
| authorships[34].author_position | middle |
| authorships[34].raw_author_name | Larissa B. Thackray |
| authorships[34].is_corresponding | False |
| authorships[34].raw_affiliation_strings | Departments of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA |
| authorships[35].author.id | https://openalex.org/A5067185663 |
| authorships[35].author.orcid | https://orcid.org/0000-0003-3358-5028 |
| authorships[35].author.display_name | Brent W. Segelke |
| authorships[35].countries | US |
| authorships[35].affiliations[0].institution_ids | https://openalex.org/I1282311441 |
| authorships[35].affiliations[0].raw_affiliation_string | Biosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA |
| authorships[35].institutions[0].id | https://openalex.org/I1282311441 |
| authorships[35].institutions[0].ror | https://ror.org/041nk4h53 |
| authorships[35].institutions[0].type | facility |
| authorships[35].institutions[0].lineage | https://openalex.org/I1282311441, https://openalex.org/I1330989302, https://openalex.org/I198811213, https://openalex.org/I4210138311 |
| authorships[35].institutions[0].country_code | US |
| authorships[35].institutions[0].display_name | Lawrence Livermore National Laboratory |
| authorships[35].author_position | middle |
| authorships[35].raw_author_name | Brent W. Segelke |
| authorships[35].is_corresponding | False |
| authorships[35].raw_affiliation_strings | Biosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA |
| authorships[36].author.id | https://openalex.org/A5091499211 |
| authorships[36].author.orcid | https://orcid.org/0000-0002-0457-6598 |
| authorships[36].author.display_name | Antonietta Lillo |
| authorships[36].countries | US |
| authorships[36].affiliations[0].institution_ids | https://openalex.org/I1343871089 |
| authorships[36].affiliations[0].raw_affiliation_string | Los Alamos National Laboratory, Bioscience Division, Los Alamos, NM 87545, USA |
| authorships[36].institutions[0].id | https://openalex.org/I1343871089 |
| authorships[36].institutions[0].ror | https://ror.org/01e41cf67 |
| authorships[36].institutions[0].type | facility |
| authorships[36].institutions[0].lineage | https://openalex.org/I1330989302, https://openalex.org/I1343871089, https://openalex.org/I198811213, https://openalex.org/I4210120050 |
| authorships[36].institutions[0].country_code | US |
| authorships[36].institutions[0].display_name | Los Alamos National Laboratory |
| authorships[36].author_position | middle |
| authorships[36].raw_author_name | Antonietta Maria Lillo |
| authorships[36].is_corresponding | False |
| authorships[36].raw_affiliation_strings | Los Alamos National Laboratory, Bioscience Division, Los Alamos, NM 87545, USA |
| authorships[37].author.id | https://openalex.org/A5111191129 |
| authorships[37].author.orcid | https://orcid.org/0000-0001-6675-6765 |
| authorships[37].author.display_name | Shivshankar Sundaram |
| authorships[37].countries | US |
| authorships[37].affiliations[0].institution_ids | https://openalex.org/I1282311441 |
| authorships[37].affiliations[0].raw_affiliation_string | Center for Bioengineering, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA |
| authorships[37].institutions[0].id | https://openalex.org/I1282311441 |
| authorships[37].institutions[0].ror | https://ror.org/041nk4h53 |
| authorships[37].institutions[0].type | facility |
| authorships[37].institutions[0].lineage | https://openalex.org/I1282311441, https://openalex.org/I1330989302, https://openalex.org/I198811213, https://openalex.org/I4210138311 |
| authorships[37].institutions[0].country_code | US |
| authorships[37].institutions[0].display_name | Lawrence Livermore National Laboratory |
| authorships[37].author_position | middle |
| authorships[37].raw_author_name | Shivshankar Sundaram |
| authorships[37].is_corresponding | False |
| authorships[37].raw_affiliation_strings | Center for Bioengineering, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA |
| authorships[38].author.id | https://openalex.org/A5091068534 |
| authorships[38].author.orcid | https://orcid.org/0000-0003-1267-3408 |
| authorships[38].author.display_name | Jesse D. Bloom |
| authorships[38].author_position | middle |
| authorships[38].raw_author_name | Jesse Bloom |
| authorships[38].is_corresponding | False |
| authorships[39].author.id | https://openalex.org/A5102805830 |
| authorships[39].author.orcid | https://orcid.org/0000-0002-6646-6781 |
| authorships[39].author.display_name | Michael S. Diamond |
| authorships[39].countries | US |
| authorships[39].affiliations[0].institution_ids | https://openalex.org/I204465549 |
| authorships[39].affiliations[0].raw_affiliation_string | Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110, USA |
| authorships[39].affiliations[1].institution_ids | https://openalex.org/I204465549 |
| authorships[39].affiliations[1].raw_affiliation_string | Pathology & Immunology, Washington University School of Medicine, St. Louis, MO 631, USA |
| authorships[39].affiliations[2].institution_ids | https://openalex.org/I204465549 |
| authorships[39].affiliations[2].raw_affiliation_string | Departments of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA |
| authorships[39].institutions[0].id | https://openalex.org/I204465549 |
| authorships[39].institutions[0].ror | https://ror.org/01yc7t268 |
| authorships[39].institutions[0].type | education |
| authorships[39].institutions[0].lineage | https://openalex.org/I204465549 |
| authorships[39].institutions[0].country_code | US |
| authorships[39].institutions[0].display_name | Washington University in St. Louis |
| authorships[39].author_position | middle |
| authorships[39].raw_author_name | Michael S. Diamond |
| authorships[39].is_corresponding | False |
| authorships[39].raw_affiliation_strings | Departments of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA, Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110, USA, Pathology & Immunology, Washington University School of Medicine, St. Louis, MO 631, USA |
| authorships[40].author.id | https://openalex.org/A5046971682 |
| authorships[40].author.orcid | https://orcid.org/0000-0002-0049-1079 |
| authorships[40].author.display_name | James E. Crowe |
| authorships[40].countries | US |
| authorships[40].affiliations[0].raw_affiliation_string | Vanderbilt Vaccine Center, Nashville, TN 3232, USA |
| authorships[40].affiliations[1].institution_ids | https://openalex.org/I901861585 |
| authorships[40].affiliations[1].raw_affiliation_string | Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA |
| authorships[40].institutions[0].id | https://openalex.org/I901861585 |
| authorships[40].institutions[0].ror | https://ror.org/05dq2gs74 |
| authorships[40].institutions[0].type | healthcare |
| authorships[40].institutions[0].lineage | https://openalex.org/I4210162197, https://openalex.org/I901861585 |
| authorships[40].institutions[0].country_code | US |
| authorships[40].institutions[0].display_name | Vanderbilt University Medical Center |
| authorships[40].author_position | middle |
| authorships[40].raw_author_name | James E. Crowe |
| authorships[40].is_corresponding | False |
| authorships[40].raw_affiliation_strings | Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA, Vanderbilt Vaccine Center, Nashville, TN 3232, USA |
| authorships[41].author.id | https://openalex.org/A5015712888 |
| authorships[41].author.orcid | https://orcid.org/0000-0001-5230-1532 |
| authorships[41].author.display_name | Robert H. Carnahan |
| authorships[41].countries | US |
| authorships[41].affiliations[0].raw_affiliation_string | Vanderbilt Vaccine Center, Nashville, TN 3232, USA |
| authorships[41].affiliations[1].institution_ids | https://openalex.org/I901861585 |
| authorships[41].affiliations[1].raw_affiliation_string | Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA |
| authorships[41].institutions[0].id | https://openalex.org/I901861585 |
| authorships[41].institutions[0].ror | https://ror.org/05dq2gs74 |
| authorships[41].institutions[0].type | healthcare |
| authorships[41].institutions[0].lineage | https://openalex.org/I4210162197, https://openalex.org/I901861585 |
| authorships[41].institutions[0].country_code | US |
| authorships[41].institutions[0].display_name | Vanderbilt University Medical Center |
| authorships[41].author_position | middle |
| authorships[41].raw_author_name | Robert H. Carnahan |
| authorships[41].is_corresponding | False |
| authorships[41].raw_affiliation_strings | Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA, Vanderbilt Vaccine Center, Nashville, TN 3232, USA |
| authorships[42].author.id | https://openalex.org/A5087736344 |
| authorships[42].author.orcid | https://orcid.org/0000-0001-6965-983X |
| authorships[42].author.display_name | Daniel Faissol |
| authorships[42].countries | US |
| authorships[42].affiliations[0].institution_ids | https://openalex.org/I1282311441 |
| authorships[42].affiliations[0].raw_affiliation_string | Computational Engineering Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA |
| authorships[42].institutions[0].id | https://openalex.org/I1282311441 |
| authorships[42].institutions[0].ror | https://ror.org/041nk4h53 |
| authorships[42].institutions[0].type | facility |
| authorships[42].institutions[0].lineage | https://openalex.org/I1282311441, https://openalex.org/I1330989302, https://openalex.org/I198811213, https://openalex.org/I4210138311 |
| authorships[42].institutions[0].country_code | US |
| authorships[42].institutions[0].display_name | Lawrence Livermore National Laboratory |
| authorships[42].author_position | last |
| authorships[42].raw_author_name | Daniel M. Faissol |
| authorships[42].is_corresponding | True |
| authorships[42].raw_affiliation_strings | Computational Engineering Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.biorxiv.org/content/biorxiv/early/2022/10/24/2022.10.21.513237.full.pdf |
| open_access.oa_status | green |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Computationally restoring the potency of a clinical antibody against SARS-CoV-2 Omicron subvariants |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10118 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9995999932289124 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2725 |
| primary_topic.subfield.display_name | Infectious Diseases |
| primary_topic.display_name | SARS-CoV-2 and COVID-19 Research |
| related_works | https://openalex.org/W2323301649, https://openalex.org/W1963574378, https://openalex.org/W2000111628, https://openalex.org/W3186246047, https://openalex.org/W2004647072, https://openalex.org/W2375279375, https://openalex.org/W2151437734, https://openalex.org/W2077622600, https://openalex.org/W4232026532, https://openalex.org/W1981153119 |
| cited_by_count | 5 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 2 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 1 |
| counts_by_year[2].year | 2023 |
| counts_by_year[2].cited_by_count | 2 |
| locations_count | 3 |
| best_oa_location.id | doi:10.1101/2022.10.21.513237 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S4306402567 |
| best_oa_location.source.issn | |
| best_oa_location.source.type | repository |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | |
| best_oa_location.source.is_core | False |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | bioRxiv (Cold Spring Harbor Laboratory) |
| best_oa_location.source.host_organization | https://openalex.org/I2750212522 |
| best_oa_location.source.host_organization_name | Cold Spring Harbor Laboratory |
| best_oa_location.source.host_organization_lineage | https://openalex.org/I2750212522 |
| best_oa_location.license | cc-by-nd |
| best_oa_location.pdf_url | https://www.biorxiv.org/content/biorxiv/early/2022/10/24/2022.10.21.513237.full.pdf |
| best_oa_location.version | acceptedVersion |
| best_oa_location.raw_type | posted-content |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by-nd |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | False |
| best_oa_location.raw_source_name | |
| best_oa_location.landing_page_url | https://doi.org/10.1101/2022.10.21.513237 |
| primary_location.id | doi:10.1101/2022.10.21.513237 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S4306402567 |
| primary_location.source.issn | |
| primary_location.source.type | repository |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | |
| primary_location.source.is_core | False |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | bioRxiv (Cold Spring Harbor Laboratory) |
| primary_location.source.host_organization | https://openalex.org/I2750212522 |
| primary_location.source.host_organization_name | Cold Spring Harbor Laboratory |
| primary_location.source.host_organization_lineage | https://openalex.org/I2750212522 |
| primary_location.license | cc-by-nd |
| primary_location.pdf_url | https://www.biorxiv.org/content/biorxiv/early/2022/10/24/2022.10.21.513237.full.pdf |
| primary_location.version | acceptedVersion |
| primary_location.raw_type | posted-content |
| primary_location.license_id | https://openalex.org/licenses/cc-by-nd |
| primary_location.is_accepted | True |
| primary_location.is_published | False |
| primary_location.raw_source_name | |
| primary_location.landing_page_url | https://doi.org/10.1101/2022.10.21.513237 |
| publication_date | 2022-10-24 |
| publication_year | 2022 |
| referenced_works | https://openalex.org/W4224289402, https://openalex.org/W3180445914, https://openalex.org/W3111431752, https://openalex.org/W4226087845, https://openalex.org/W4220886953, https://openalex.org/W4283779466, https://openalex.org/W4310098546, https://openalex.org/W4225691034, https://openalex.org/W4221116249, https://openalex.org/W4281754639, https://openalex.org/W4286009139, https://openalex.org/W3042323010, https://openalex.org/W3199394546, https://openalex.org/W2121688928, https://openalex.org/W4205331651, https://openalex.org/W2017956110, https://openalex.org/W4200520345, https://openalex.org/W2780523853, https://openalex.org/W2023490488, https://openalex.org/W4286382909, https://openalex.org/W4289782607, https://openalex.org/W3206187363, https://openalex.org/W3025744748, https://openalex.org/W4220829301, https://openalex.org/W2017577931, https://openalex.org/W4280650748, https://openalex.org/W4221063567, https://openalex.org/W4306153754, https://openalex.org/W4296211388, https://openalex.org/W2074473216, https://openalex.org/W4220682469, https://openalex.org/W4353040051, https://openalex.org/W2909255640, https://openalex.org/W2110483430, https://openalex.org/W2049631297, https://openalex.org/W2949223833, https://openalex.org/W2109154308, https://openalex.org/W1976499671, https://openalex.org/W2313116527, https://openalex.org/W2067174909, https://openalex.org/W2106140689, https://openalex.org/W3006072350, https://openalex.org/W1969189143, https://openalex.org/W2345664734, https://openalex.org/W2555870966, https://openalex.org/W2158307923, https://openalex.org/W2132629607, https://openalex.org/W1031578623, https://openalex.org/W2150192011, https://openalex.org/W3177500196, https://openalex.org/W1908675203, https://openalex.org/W3040899749, https://openalex.org/W3020828664, https://openalex.org/W3093768302, https://openalex.org/W4206135665, https://openalex.org/W3133782701, https://openalex.org/W2142758749, https://openalex.org/W3035628751, https://openalex.org/W4311417717, https://openalex.org/W3213779066, https://openalex.org/W2593511418, https://openalex.org/W2953320394, https://openalex.org/W2606915259, https://openalex.org/W3093295276, https://openalex.org/W2899714098, https://openalex.org/W3083406432, https://openalex.org/W2144081223, https://openalex.org/W2180229411, https://openalex.org/W2786390877, https://openalex.org/W2154714625, https://openalex.org/W4226525051 |
| referenced_works_count | 71 |
| abstract_inverted_index., | 15 |
| abstract_inverted_index.. | 29, 58 |
| abstract_inverted_index.3 | 67 |
| abstract_inverted_index.4 | 77 |
| abstract_inverted_index.5 | 28 |
| abstract_inverted_index.6 | 57 |
| abstract_inverted_index.a | 65, 92, 103 |
| abstract_inverted_index.4, | 27, 56 |
| abstract_inverted_index.TM | 51 |
| abstract_inverted_index.We | 107 |
| abstract_inverted_index.an | 198 |
| abstract_inverted_index.in | 38, 75, 114, 161 |
| abstract_inverted_index.is | 64, 70, 79, 102, 212 |
| abstract_inverted_index.it | 223 |
| abstract_inverted_index.of | 7, 33, 153, 174, 176 |
| abstract_inverted_index.or | 219, 233 |
| abstract_inverted_index.to | 81, 96, 109, 112, 200, 229 |
| abstract_inverted_index.we | 133 |
| abstract_inverted_index.Our | 190 |
| abstract_inverted_index.The | 1 |
| abstract_inverted_index.and | 11, 52, 78, 120, 150, 158, 169 |
| abstract_inverted_index.but | 16 |
| abstract_inverted_index.can | 23, 196 |
| abstract_inverted_index.how | 19 |
| abstract_inverted_index.its | 53, 61 |
| abstract_inverted_index.not | 215 |
| abstract_inverted_index.our | 136, 210 |
| abstract_inverted_index.the | 5, 31, 34, 127, 164 |
| abstract_inverted_index.BA.1 | 119 |
| abstract_inverted_index.Deep | 171 |
| abstract_inverted_index.Here | 132 |
| abstract_inverted_index.With | 30 |
| abstract_inverted_index.also | 17 |
| abstract_inverted_index.drug | 45 |
| abstract_inverted_index.late | 39 |
| abstract_inverted_index.like | 60 |
| abstract_inverted_index.lost | 47 |
| abstract_inverted_index.many | 41, 151 |
| abstract_inverted_index.show | 134 |
| abstract_inverted_index.such | 88 |
| abstract_inverted_index.tens | 175 |
| abstract_inverted_index.that | 69, 135, 155, 193 |
| abstract_inverted_index.this | 142 |
| abstract_inverted_index.used | 43 |
| abstract_inverted_index.vivo | 115, 162 |
| abstract_inverted_index.with | 72, 83, 91 |
| abstract_inverted_index.1–3 | 14 |
| abstract_inverted_index.2021, | 40 |
| abstract_inverted_index.BA.5. | 170 |
| abstract_inverted_index.Delta | 130, 149 |
| abstract_inverted_index.broad | 183 |
| abstract_inverted_index.class | 66 |
| abstract_inverted_index.could | 224 |
| abstract_inverted_index.data, | 222 |
| abstract_inverted_index.drugs | 13 |
| abstract_inverted_index.known | 93 |
| abstract_inverted_index.other | 73 |
| abstract_inverted_index.rapid | 226 |
| abstract_inverted_index.viral | 21 |
| abstract_inverted_index.while | 123, 205 |
| abstract_inverted_index.BA.1.1 | 121 |
| abstract_inverted_index.enable | 225 |
| abstract_inverted_index.escape | 22, 188, 203, 231, 236 |
| abstract_inverted_index.rescue | 113 |
| abstract_inverted_index.sought | 108 |
| abstract_inverted_index.target | 201 |
| abstract_inverted_index.BA.1.1, | 168 |
| abstract_inverted_index.Because | 209 |
| abstract_inverted_index.Omicron | 36, 118 |
| abstract_inverted_index.Rapidly | 86 |
| abstract_inverted_index.address | 230 |
| abstract_inverted_index.against | 99, 117, 126, 148, 163 |
| abstract_inverted_index.binding | 221 |
| abstract_inverted_index.concern | 154 |
| abstract_inverted_index.curtail | 24 |
| abstract_inverted_index.driven, | 214 |
| abstract_inverted_index.options | 26 |
| abstract_inverted_index.potency | 147, 184 |
| abstract_inverted_index.profile | 95 |
| abstract_inverted_index.promise | 6 |
| abstract_inverted_index.quickly | 20 |
| abstract_inverted_index.replace | 82 |
| abstract_inverted_index.restore | 97 |
| abstract_inverted_index.results | 191 |
| abstract_inverted_index.reveals | 180 |
| abstract_inverted_index.strains | 122, 165 |
| abstract_inverted_index.suggest | 192 |
| abstract_inverted_index.tested, | 166 |
| abstract_inverted_index.variant | 37 |
| abstract_inverted_index.without | 185 |
| abstract_inverted_index.ABSTRACT | 0 |
| abstract_inverted_index.COVID-19 | 2 |
| abstract_inverted_index.Evusheld | 50 |
| abstract_inverted_index.achieves | 141 |
| abstract_inverted_index.antibody | 44, 68, 199 |
| abstract_inverted_index.approach | 211 |
| abstract_inverted_index.clinical | 94 |
| abstract_inverted_index.dominant | 129 |
| abstract_inverted_index.efficacy | 98, 116, 125 |
| abstract_inverted_index.emerged, | 157 |
| abstract_inverted_index.emerging | 100 |
| abstract_inverted_index.existing | 84 |
| abstract_inverted_index.improves | 182 |
| abstract_inverted_index.mitigate | 235 |
| abstract_inverted_index.multiple | 202 |
| abstract_inverted_index.optimize | 197 |
| abstract_inverted_index.pandemic | 3 |
| abstract_inverted_index.potency, | 48 |
| abstract_inverted_index.potency. | 208 |
| abstract_inverted_index.products | 46 |
| abstract_inverted_index.provides | 159 |
| abstract_inverted_index.redesign | 110 |
| abstract_inverted_index.response | 227 |
| abstract_inverted_index.revealed | 18 |
| abstract_inverted_index.scanning | 173 |
| abstract_inverted_index.variant. | 131 |
| abstract_inverted_index.variants | 101, 152, 179, 232 |
| abstract_inverted_index.COV2-2130 | 111 |
| abstract_inverted_index.WA1/2020, | 167 |
| abstract_inverted_index.antibody, | 139 |
| abstract_inverted_index.effective | 25 |
| abstract_inverted_index.emergence | 32 |
| abstract_inverted_index.enriching | 207 |
| abstract_inverted_index.including | 49 |
| abstract_inverted_index.increases | 145 |
| abstract_inverted_index.incurring | 186 |
| abstract_inverted_index.modifying | 87 |
| abstract_inverted_index.requiring | 216 |
| abstract_inverted_index.strategy. | 106 |
| abstract_inverted_index.thousands | 177 |
| abstract_inverted_index.variants, | 204 |
| abstract_inverted_index.COV2-2130, | 63 |
| abstract_inverted_index.SARS-CoV-2 | 35 |
| abstract_inverted_index.additional | 187 |
| abstract_inverted_index.antibodies | 74, 90 |
| abstract_inverted_index.approaches | 195 |
| abstract_inverted_index.cilgavimab | 55 |
| abstract_inverted_index.clinically | 42 |
| abstract_inverted_index.compatible | 71 |
| abstract_inverted_index.compelling | 104 |
| abstract_inverted_index.high-value | 89 |
| abstract_inverted_index.iterations | 218 |
| abstract_inverted_index.mitigation | 105 |
| abstract_inverted_index.monoclonal | 8 |
| abstract_inverted_index.mutational | 172 |
| abstract_inverted_index.objective, | 143 |
| abstract_inverted_index.progenitor | 62 |
| abstract_inverted_index.protection | 160 |
| abstract_inverted_index.redesigned | 138 |
| abstract_inverted_index.strategies | 228 |
| abstract_inverted_index.Cilgavimab, | 59 |
| abstract_inverted_index.approaches. | 85 |
| abstract_inverted_index.challenging | 80 |
| abstract_inverted_index.combination | 76 |
| abstract_inverted_index.maintaining | 124 |
| abstract_inverted_index.pseudovirus | 178 |
| abstract_inverted_index.therapeutic | 12 |
| abstract_inverted_index.underscored | 4 |
| abstract_inverted_index.constituent, | 54 |
| abstract_inverted_index.experimental | 217 |
| abstract_inverted_index.liabilities. | 189 |
| abstract_inverted_index.pre-existing | 220 |
| abstract_inverted_index.prophylactic | 10 |
| abstract_inverted_index.subsequently | 156 |
| abstract_inverted_index.computational | 194 |
| abstract_inverted_index.pre-emptively | 234 |
| abstract_inverted_index.antibody-based | 9 |
| abstract_inverted_index.neutralization | 146 |
| abstract_inverted_index.simultaneously | 144, 206 |
| abstract_inverted_index.2130-1-0114-112 | 181 |
| abstract_inverted_index.computationally | 137, 213 |
| abstract_inverted_index.2130-1-0114-112, | 140 |
| abstract_inverted_index.vulnerabilities. | 237 |
| abstract_inverted_index.contemporaneously | 128 |
| cited_by_percentile_year.max | 97 |
| cited_by_percentile_year.min | 90 |
| corresponding_author_ids | https://openalex.org/A5087736344 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 43 |
| corresponding_institution_ids | https://openalex.org/I1282311441 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8199999928474426 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.66103896 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |